According to reports from Business Standard, Aarey Drugs & Pharmaceuticals reported a 25.55% decline in standalone net profit to ₹1.02 crore in the quarter ended June 2026, compared to ₹1.37 crore in the corresponding quarter of the previous year. The pharmaceutical company's financial performance showed significant pressure during the first quarter of fiscal 2026.
As reported by Business Standard, the company's sales declined sharply by 56.34% to ₹44.63 crore in Q1 FY2026, down from ₹102.21 crore in the same quarter of the previous financial year. This substantial revenue decline indicates challenging market conditions or operational issues affecting the pharmaceutical manufacturer's business performance.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) compressed to 2.94% in Q1 FY2026, compared to 1.67% in the corresponding quarter of the previous year. Additionally, PBDT (Profit Before Depreciation and Tax) declined 39% to ₹1.36 crore from ₹2.22 crore year-on-year, while PBT (Profit Before Tax) fell 71% to ₹0.51 crore from ₹1.73 crore in the same period last year.
As reported by Business Standard, the financial results were published on August 15, 2026, indicating the company's performance during the quarter ended June 2026. The significant decline in both profitability and revenue metrics suggests operational challenges that the pharmaceutical company faced during this quarter, reflecting broader industry or company-specific factors affecting its business performance.
